{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:43:57Z","timestamp":1790844237705,"version":"4.1.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> \u03b2-lactams remain the cornerstone of the empirical therapy to treat various bacterial infections. This systematic review aimed to analyze the data describing the dosing regimen of \u03b2-lactams.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Systematic scientific and grey literature was performed in accordance with Preferred Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The studies were retrieved and screened on the basis of pre-defined exclusion and inclusion criteria. The cohort studies, randomized controlled trials (RCT) and case reports that reported the dosing schedule of \u03b2-lactams are included in this study.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 52 studies met the inclusion criteria, of which 40 were cohort studies, 2 were case reports and 10 were RCTs. The majority of the studies (34\/52) studied the pharmacokinetic (PK) parameters of a drug. A total of 20 studies proposed dosing schedule in pediatrics while 32 studies proposed dosing regimen among adults. Piperacillin (12\/52) and Meropenem (11\/52) were the most commonly used \u03b2-lactams used in hospitalized patients. As per available evidence, continuous infusion is considered as the most appropriate mode of administration to optimize the safety and efficacy of the treatment and improve the clinical outcomes.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Appropriate antibiotic therapy is challenging due to pathophysiological changes among different age groups. The optimization of pharmacokinetic\/pharmacodynamic parameters is useful to support alternative dosing regimens such as an increase in dosing interval, continuous infusion, and increased bolus doses.<\/jats:p>","DOI":"10.3389\/fphar.2022.964005","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T06:23:52Z","timestamp":1663741432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Dose optimization of \u03b2-lactams antibiotics in pediatrics and adults: A systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Abdul","family":"Haseeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani Saleh","family":"Faidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal F.","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Essam","family":"Elrggal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad J.","family":"Mahrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa S. Almarzoky","family":"Abuhussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla A.","family":"Obaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Algethamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullmoin","family":"AlQarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim A.","family":"Khogeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikria","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami S.","family":"Ashgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozan Mohammad","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Mutlaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayyra","family":"Fatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"624639","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: A narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front. Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/antibiotics9100676","article-title":"Some suggestions from PK\/PD principles to contain resistance in the clinical setting\u2014focus on ICU patients and gram-negative strains","volume":"9","author":"Adembri","year":"2020","journal-title":"Antibiotics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/antibiotics10030280","article-title":"Antimicrobial stewardship program implementation in a Saudi medical city: An exploratory case study","volume":"10","author":"Alghamdi","year":"2021","journal-title":"Antibiotics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: A critical review","volume":"19","author":"Andes","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jiph.2019.07.003","article-title":"Community pharmacists as antibiotic stewards: A qualitative study exploring the current status of antibiotic stewardship program in bahawalpur, Pakistan.","volume":"13","author":"Atif","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40262-018-0682-1","article-title":"Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance","volume":"58","author":"B\u00e9ranger","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40262-017-0602-9","article-title":"Population pharmacokinetic model to optimize cefotaxime dosing regimen in critically ill children","volume":"57","author":"B\u00e9ranger","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B8","first-page":"87","article-title":"Simplified techniques for analysis","volume-title":"Toxicity of \u03b2-lactam antibiotics: Pathophysiology, molecular biology and possible recovery strategies","author":"Bozcal","year":"2017"},{"key":"B9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jac\/49.1.121","article-title":"Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections","volume":"49","author":"Buijk","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/jac\/dku195","article-title":"Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: Non-standard dosing approaches are required to achieve therapeutic exposures","volume":"69","author":"Carlier","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/idr.s10018","article-title":"Prevention strategies for antimicrobial resistance: A systematic review of the literature","volume":"3","author":"Caron","year":"2010","journal-title":"Infect. Drug Resist."},{"key":"B12","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1186\/cc8941","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","author":"Chapuis","year":"2010","journal-title":"Crit. Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1592\/phco.28.6.691","article-title":"Steady\u2010state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients","volume":"28","author":"Cheatham","year":"2008","journal-title":"Pharmacotherapy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5863\/1551-6776-22.6.467","article-title":"Therapeutic drug monitoring of prolonged infusion aztreonam for multi-drug resistant Pseudomonas aeruginosa: A case report","volume":"22","author":"Cies","year":"","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1097\/pcc.0000000000001497","article-title":"Ceftaroline for suspected or confirmed invasive methicillin-resistant Staphylococcus aureus: A pharmacokinetic case series","volume":"19","author":"Cies","year":"","journal-title":"Pediatr. Crit. Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5863\/1551-6776-22.4.276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children","volume":"22","author":"Cies","year":"","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1097\/pcc.0000000000001497","article-title":"Ceftaroline for suspected or confirmed invasive methicillin-resistant Staphylococcus aureus: A pharmacokinetic case series.","volume":"19","author":"Cies","year":"","journal-title":"Pediatr. Crit. Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1002\/phar.1567","article-title":"Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient","volume":"35","author":"Cies","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/jac\/dky574","article-title":"Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children","volume":"74","author":"Cies","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/INF.0b013e3182a743c7","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children.","volume":"33","author":"Cies","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.medin.2015.07.009","article-title":"Antibiotic dose optimization in critically ill patients","volume":"39","author":"Cotta","year":"2015","journal-title":"Med. Intensiva"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1128\/AAC.04232-14","article-title":"Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia","volume":"59","author":"Cousson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00134-010-2105-0","article-title":"Optimization of meropenem dosage in the critically ill population based on renal function","volume":"37","author":"Crandon","year":"2011","journal-title":"Intensive Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1128\/AAC.01183-09","article-title":"Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"521933","DOI":"10.3389\/fphar.2020.521933","article-title":"Dose rationale for amoxicillin in neonatal sepsis when referral is not possible","volume":"11","author":"D\u2019Agate","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"dkw496","DOI":"10.1093\/jac\/dkw496","article-title":"Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery","volume":"72","author":"De Cock","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1128\/aac.01368-15","article-title":"Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children","volume":"59","author":"De Cock","year":"2015","journal-title":"Antimicrob. Agents Chemother.Antimicrobial Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/jac\/dkx093","article-title":"Dose optimization of piperacillin\/tazobactam in critically ill children","volume":"72","author":"De Cock","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B29","first-page":"1302","article-title":"Extended versus bolus infusion of meropenem and piperacillin: A pharmacokinetic analysis","volume":"80","author":"De Waele","year":"","journal-title":"Minerva Anestesiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: A randomised controlled trial","volume":"40","author":"De Waele","year":"","journal-title":"Intensive Care Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/14787210.2017.1338139","article-title":"Optimizing \u03b2-lactams treatment in critically-ill patients using pharmacokinetics\/pharmacodynamics targets: Are first conventional doses effective?","volume":"15","author":"Delattre","year":"2017","journal-title":"Expert Rev. anti. Infect. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/ipc.0b013e31822e9bf5","article-title":"Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center","volume":"19","author":"Dow","year":"","journal-title":"Infect. Dis. Clin. Pract. Balt. Md."},{"key":"B33","first-page":"413","volume-title":"Retrospective Study of Prolonged Versus Intermittent Infusion Piperacillin-Tazobactam and Meropenem in Intensive Care Unit Patients at an Academic Medical Center","author":"Dow","year":""},{"key":"B34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial.","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: A systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1128\/AAC.00521-12","article-title":"Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections","volume":"56","author":"Felton","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fphar.2020.00551","article-title":"Model-informed precision dosing of vancomycin in hospitalized children: Implementation and adoption at an academic children's hospital","volume":"11","author":"Frymoyer","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1248\/bpb.32.1139","article-title":"Pharmacokinetics of ceftriaxione, a third-generation cephalosporin, in pediatric patients","volume":"32","author":"Fukumoto","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"B39","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2125.2011.04117.x","article-title":"Ceftazidime dosage regimen in intensive care unit patients: From a population pharmacokinetic approach to clinical practice via Monte Carlo simulations","volume":"73","author":"Georges","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1128\/AAC.01149-05","article-title":"Prospective determination of plasma imipenem concentrations in critically ill children","volume":"50","author":"Giannoni","year":"2006","journal-title":"Antimicrob. Agents Chemother.Antimicrobial Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s00134-022-06679-0","article-title":"The TARGET trial as a plea for model-informed precision dosing of piperacillin\/tazobactam in patients with sepsis","volume":"48","author":"Gijsen","year":"2022","journal-title":"Intensive Care Med."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz067","article-title":"Successful implementation of an antibiotic stewardship program in an academic dental practice","volume-title":"Open forum infectious diseases","author":"Gross","year":"2019"},{"key":"B43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1128\/CMR.00022-16","article-title":"Continuous and prolonged intravenous \u03b2-lactam dosing: Implications for the clinical laboratory","volume":"29","author":"Grupper","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit. Care"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1128\/AAC.45.9.2436-2440.2001","article-title":"Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model","volume":"45","author":"Gustafsson","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jac5.1084","article-title":"Perceptions and practices for beta\u2010lactam antibiotic dosing, administration, and monitoring in critically ill patients: Current views and use among critical care and infectious diseases pharmacists","volume":"2","author":"Hammond","year":"2019","journal-title":"J. Am. Coll. Clin. Pharm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/s0002-9610(00)00388-3","article-title":"Intermittent and continuous ceftazidime infusion for critically ill trauma patients","volume":"179","author":"Hanes","year":"2000","journal-title":"Am. J. Surg."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s10096-019-03535-w","article-title":"Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis","volume":"38","author":"Hartman","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: A systematic review of current literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/antibiotics11030409","article-title":"A systematic review on clinical safety and efficacy of vancomycin loading dose in critically ill patients","volume":"11","author":"Haseeb","year":"2022","journal-title":"Antibiotics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jsps.2020.08.005","article-title":"Evaluation of antimicrobial stewardship programs (ASPs) and their perceived level of success at makkah region hospitals, kingdom of Saudi arabia","volume":"28","author":"Haseeb","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"570238","DOI":"10.3389\/fphar.2020.570238","article-title":"Evaluation of a multidisciplinary antimicrobial stewardship program in a Saudi critical care unit: A quasi-experimental study","volume":"11","author":"Haseeb","year":"","journal-title":"Front. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/antibiotics10121454","article-title":"Dose optimization of colistin: A systematic review","volume":"10","author":"Haseeb","year":"","journal-title":"Antibiotics"},{"key":"B54","first-page":"1807","volume-title":"A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia","author":"He","year":"2020"},{"key":"B55","first-page":"205","volume-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019"},{"key":"B56","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1345\/aph.1S032","article-title":"Standard versus prolonged doripenem infusion for treatment of gram-negative infections","volume":"47","author":"Hsaiky","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jac\/47.4.421","article-title":"The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients","volume":"47","author":"Joynt","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/jac\/dkr137","article-title":"Impact of antimicrobial stewardship in critical care: A systematic review","volume":"66","author":"Kaki","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e00249-20","DOI":"10.1128\/AAC.00249-20","article-title":"Dose optimization of cefpirome based on population pharmacokinetics and target attainment during extracorporeal membrane oxygenation","volume":"64","author":"Kang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: How well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2165\/00003495-200565170-00006","article-title":"Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: A systematic review of pharmacokinetic and pharmacodynamic parameters","volume":"65","author":"Kasiakou","year":"2005","journal-title":"Drugs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0149623","DOI":"10.1371\/journal.pone.0149623","article-title":"Perceptions and practices of community pharmacists towards antimicrobial stewardship in the state of selangor, Malaysia","volume":"11","author":"Khan","year":"2016","journal-title":"PLoS One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00228-020-02939-4","article-title":"Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia","volume":"76","author":"Khan","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13613-019-0622-8","article-title":"Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: Implications for empirical therapy against gram-negative bacteria","volume":"10","author":"Kothekar","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"B65","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.rmclc.2016.08.001","article-title":"Optimizing antimicrobial pharmacodynamics: A guide for your stewardship program","volume":"27","author":"Kuti","year":"2016","journal-title":"Rev. Medica Clin. Las Condes"},{"key":"B66","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: Continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40121-016-0139-5","article-title":"Clinical impact of an antibiotic stewardship program at a children's hospital.","volume":"6","author":"Lee","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J. Infect. Dis."},{"key":"B69","first-page":"344","volume":"21","author":"Lesprit","year":"2008","journal-title":"Hosp. Antibiot. Steward."},{"key":"B70","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"","journal-title":"Clin. Infect. Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.diagmicrobio.2007.03.015","article-title":"Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae","volume":"58","author":"Lodise","year":"","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijantimicag.2008.10.025","article-title":"Clinical cure of ventilator-associated pneumonia treated with piperacillin\/tazobactam administered by continuous or intermittent infusion","volume":"33","author":"Lorente","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.clinthera.2007.11.003","article-title":"Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review","volume":"29","author":"Lorente","year":"2007","journal-title":"Clin. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1345\/aph.1G467","article-title":"Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli","volume":"40","author":"Lorente","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1128\/AAC.00997-16","article-title":"Population pharmacokinetics and dosing regimen optimization of meropenem in cerebrospinal fluid and plasma in patients with meningitis after neurosurgery","volume":"60","author":"Lu","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-014-0480-6","article-title":"Antibiotic stewardship in the intensive care unit","volume":"18","author":"Luyt","year":"2014","journal-title":"Crit. Care (Houten)."},{"key":"B77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0924-8579(02)00027-4","article-title":"Developments in PK\/PD: Optimising efficacy and prevention of resistance. A critical review of PK\/PD in in vitro models","volume":"19","author":"MacGowan","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1128\/AAC.41.9.2053","article-title":"In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"41","author":"Manduru","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11908-018-0613-1","article-title":"Pharmacokinetic\/pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients","volume":"20","author":"Masich","year":"","journal-title":"Curr. Infect. Dis. Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11908-018-0613-1","article-title":"Pharmacokinetic\/pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients","volume":"20","author":"Masich","year":"","journal-title":"Curr. Infect. Dis. Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2334-7-21","article-title":"Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: A prospective observational study","volume":"7","author":"Mettler","year":"2007","journal-title":"BMC Infect. Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"B84","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-Based dose adjustment: Facts and fables.","volume":"73","author":"Mouton","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1128\/AAC.48.5.1713-1718.2004","article-title":"Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141","volume":"48","author":"Mouton","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B86","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/MCC.0b013e3282e2a98f","article-title":"Continuous infusion of beta-lactams","volume":"13","author":"Mouton","year":"2007","journal-title":"Curr. Opin. Crit. Care"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B88","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1128\/AAC.02089-15","article-title":"Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob. Agents Chemother.Antimicrobial Agents Chemother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0924-8579(01)00329-6","article-title":"Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia","volume":"17","author":"Nicolau","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: A step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1248\/bpb.31.316","article-title":"Effect of severity disease on the pharmacokinetics of cefuroxime in children with multiple organ system failure","volume":"31","author":"Olguin","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","article-title":"Pharmacokinetic and pharmacodynamic principles of anti-infective dosing","volume":"38","author":"Onufrak","year":"2016","journal-title":"Clin. Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2004.08.019","article-title":"Assessment of pharmacokinetic\u2013pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae","volume":"51","author":"Owens","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/antibiotics9020065","article-title":"Strategies to combat multidrug-resistant and persistent infectious diseases","volume":"9","author":"Pacios","year":"2020","journal-title":"Antibiotics"},{"key":"B95","volume-title":"Beta lactam antibiotics","author":"Pandey","year":"2020"},{"key":"B96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.chest.2019.01.013","article-title":"Principles and practice of antibiotic stewardship in the ICU","volume":"156","author":"Pickens","year":"2019","journal-title":"Chest"},{"key":"B97","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1093\/cid\/ciu542","article-title":"Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention","volume":"59","author":"Pollack","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet. Infect. Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care?","volume":"59","author":"Roberts","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"B100","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijantimicag.2009.10.008","article-title":"First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis","volume":"35","author":"Roberts","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1128\/aac.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B102","first-page":"462","article-title":"Evaluating the appropriate use of piperacillin\/tazobactam in a community health system: A retrospective chart review","volume":"38","author":"Shah","year":"2013","journal-title":"P Throughput"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cmi.2015.05.002","article-title":"Optimization of dosing regimens and dosing in special populations","volume":"21","author":"Sime","year":"","journal-title":"Clin. Microbiol. Infect."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e003393","DOI":"10.1136\/bmjgh-2020-003393","article-title":"Antibiotic overuse in the primary health care setting: A secondary data analysis of standardised patient studies from India, China and Kenya","volume":"5","author":"Sulis","year":"2020","journal-title":"BMJ Glob. Health"},{"key":"B106","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"B107","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/01.pcc.0000538117.18545.8d","article-title":"Abstract PCCLB-32: Optimal dosing of meropenem in critically ill asian children receiving continuous renal replacement therapy using population pharmacokinetics","volume":"19","author":"Tan","year":"2018","journal-title":"Pediatr. Crit. Care Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e02336-18","DOI":"10.1128\/AAC.02336-18","article-title":"Population pharmacokinetics and dosing optimization of amoxicillin in neonates and young infants","volume":"63","author":"Tang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.7860\/JCDR\/2013\/5239.3052","article-title":"The beta lactam antibiotics as an empirical therapy in a developing country: An update on their current status and recommendations to counter the resistance against them","volume":"7","author":"Thakuria","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/2047-2994-3-33","article-title":"Evaluation of early implementations of antibiotic stewardship program initiatives in nine Dutch hospitals","volume":"3","author":"van Limburg","year":"2014","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-019-4245-3","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) in East Africa: Red alert or red herring?","volume":"19","author":"Wangai","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B112","volume-title":"Newcastle-Ottawa quality assessment scale cohort studies","author":"Wells","year":"2014"},{"key":"B113","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jcph.1752","article-title":"Population pharmacokinetics and dosing optimization of amoxicillin in Chinese infants","volume":"61","author":"Wu","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00228-018-02606-9","article-title":"Pharmacokinetics of meropenem in plasma and cerebrospinal fluid in patients with intraventricular hemorrhage after lateral ventricle drainage","volume":"75","author":"Xu","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1248\/bpb.b15-00334","article-title":"Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass","volume":"38","author":"Yokoyama","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"B116","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s11096-016-0286-5","article-title":"The pharmacokinetics of ampicillin\u2013sulbactam in anuric patients: Dosing optimization for prophylaxis during cardiovascular surgery","volume":"38","author":"Yokoyama","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"B117","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jiac.2017.09.005","article-title":"Dosing optimization of meropenem based on a pharmacokinetic analysis in patients receiving hemodiafiltration and an in vitro model","volume":"24","author":"Yokoyama","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"B118","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1592\/phco.31.8.767","article-title":"The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: A multicenter study","volume":"31","author":"Yost","year":"2011","journal-title":"Pharmacotherapy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.964005\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T06:24:07Z","timestamp":1663741447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.964005\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":118,"alternative-id":["10.3389\/fphar.2022.964005"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.964005","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"article-number":"964005"}}